These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11323951)

  • 1. Diet drugs and cardiac valvulopathy: a survey of dental patients.
    Rudin R; Carpenter W
    J Calif Dent Assoc; 2000 Dec; 28(12):955-9. PubMed ID: 11323951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anorexigen-induced cardiac valvulopathy and female gender.
    Naqvi TZ; Gross SB
    Curr Womens Health Rep; 2003 Apr; 3(2):116-25. PubMed ID: 12628081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of fenfluramine/dexfenfluramine-induced cardiac valvulopathy.
    Pallasch TJ
    J Calif Dent Assoc; 1999 May; 27(5):400-4. PubMed ID: 10528558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Appetite suppressants and heart valve disorders].
    Adams C; Cohen A
    Arch Mal Coeur Vaiss; 1999 Sep; 92(9):1213-9. PubMed ID: 10533670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
    Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
    N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appetite-suppressant drugs and valvular heart disease.
    Shapiro S
    N Engl J Med; 1999 Feb; 340(6):477-8; author reply 478-80. PubMed ID: 9988622
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Nov; 46(45):1061-6. PubMed ID: 9385873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
    Sachdev M; Miller WC; Ryan T; Jollis JG
    Am Heart J; 2002 Dec; 144(6):1065-73. PubMed ID: 12486432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taking things to heart.
    Hess MA
    J Am Diet Assoc; 2004 Jul; 104(7):1073; author reply 1073-4. PubMed ID: 15215760
    [No Abstract]   [Full Text] [Related]  

  • 10. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
    JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart valve disorders and appetite-suppressant drugs.
    Jick H
    JAMA; 2000 Apr; 283(13):1738-40. PubMed ID: 10755501
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiac valvulopathy.
    Alexander RE
    J Am Dent Assoc; 2000 Jul; 131(7):862, 864, 866 passim. PubMed ID: 10916324
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
    JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
    Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
    Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Operation for anorexigen-associated valvular heart disease.
    Caccitolo JA; Connolly HM; Rubenson DS; Orszulak TA; Schaff HV
    J Thorac Cardiovasc Surg; 2001 Oct; 122(4):656-64. PubMed ID: 11581595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
    Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
    N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography.
    Roldan CA; Gelgand EA; Decker P; Prasad A; Shively BK
    Am J Cardiol; 2002 Dec; 90(11):1269-73. PubMed ID: 12450616
    [No Abstract]   [Full Text] [Related]  

  • 18. Appetite-suppressing drugs and valvular heart disease.
    Cannistra LB; Gaasch WH
    Cardiol Rev; 1999; 7(6):356-61. PubMed ID: 11208248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appetite-suppressant drugs and valvular heart disease.
    Williamson DF; Yanovski SZ
    N Engl J Med; 1999 Feb; 340(6):476; author reply 478-80. PubMed ID: 9988618
    [No Abstract]   [Full Text] [Related]  

  • 20. More on heart disease and diet pills.
    Harv Heart Lett; 2000 Jul; 10(11):5-6. PubMed ID: 10877859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.